MedPath

Repetitive transcranial magnetic stimulation for bipolar depression.

Phase 2
Recruiting
Conditions
Bipolar disorder
Registration Number
JPRN-jRCTs032180138
Lead Sponsor
oda Takamasa
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
96
Inclusion Criteria

Each potential subject must satisfy all of the following criteria to be enrolled in the study.
1. Subjects must be meet Diagnostic and Statistical Manual of Mental Disorders-5 Edition (DSM-5) diagnostic criteria for Bipolar Disorders (included type I and II), and depressive episode without rapid cycler.
2. Subjects must be a man or woman, 20 to 75 years of age, inclusive.
3. Have a Hamilton Rating Scale for Depression total score not less than 18.
4. Have a current depressive episode under 3 years.
5. Subject must have had an inadequate response in the current episode of depressive episode to at least one pharmacotherapy during 8 weeks as below.
Lithium, appropriate blood concentration greater than 0.8mEq/L
Quetiapine, 300mg/day
Olanzapine, 5-20mg/day
Lurasidone, 20-60mg/day
Lamotrigine, 200mg/day

Exclusion Criteria

Any potential subject who meets the following criteria will be excluded from participating in the study.
1. Subject has a current or prior diagnosis of a psychotic disorder, Obsessive-compulsive disorder, Post Traumatic Stress Disorder, or Eating disorder.
2. Subject has a treatment history with Electro-convulsive therapy, Repetitive transcranial magnetic stimulation, Deep Brain Stimulation, Transcranial Direct Current Stimulation, or Vagus nerve stimulation.
3. Subject is a woman who is pregnant.
4. Patients with a medical history of convulsive disorders (e.g., epilepsy) and patients with the close relatives (first-degree relatives) with the same history.
5. Subject has a current or prior diagnosis of a Neurological disorder or Organic mental disorder.
6. Has a history of substance abuse (drug or alchol) or dependence.
7. Patients with magnetic bodies such as pacemakers, cochlear implants, and intracranial clips (screening is performed by supplementary document).
8. Has a serious metabolic or endocrine disturbances.
9. Subject has a serious suicidal ideation (HAM-D suicidal ideation sub-scale score not less than 3)
10. Patients receiving medication (e.g. Neuroleptics, Tricyclic antidepressants) that decreases seizures threshold.
11. Subject considered by the principal investigator and sub-investigator(s) to be inappropriate for the safe conduct of the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath